Bone marrow microenvironment in multiple myeloma progression.
about
MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow MicroenvironmentMicro-RNAs, New performers in multiple myeloma bone marrow microenvironmentOsteoblast-adipocyte lineage plasticity in tissue development, maintenance and pathologyDrug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cellsRecent advances in antimultiple myeloma drug development.Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed, Lenalidomide Refractory Multiple Myeloma.TPL2 kinase regulates the inflammatory milieu of the myeloma nicheInhibitor of apoptosis proteins as therapeutic targets in multiple myeloma.Argonaute 2 promotes myeloma angiogenesis via microRNA dysregulation.Altered cytokine and chemokine profiles in multiple myeloma and its precursor diseaseCancer associated fibroblasts and tumor growth: focus on multiple myelomaCutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma.Induction of malignant plasma cell proliferation by eosinophilsCD138-negative myeloma cells regulate mechanical properties of bone marrow stromal cells through SDF-1/CXCR4/AKT signaling pathwayBone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression.Myeloma cell-derived Runx2 promotes myeloma progression in bone.Higher Decorin Levels in Bone Marrow Plasma Are Associated with Superior Treatment Response to Novel Agent-Based Induction in Patients with Newly Diagnosed Myeloma - A Retrospective Study.Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression.HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomideHigh level of interleukin-10 in serum predicts poor prognosis in multiple myeloma.Piperlongumine induces apoptosis and reduces bortezomib resistance by inhibiting STAT3 in multiple myeloma cells.Multiple myeloma: the bone marrow microenvironment and its relation to treatment.Multiple myeloma maintenance therapy: a review of the pharmacologic treatment.Association of Chromosomal Translocation and MiRNA Expression with The Pathogenesis of Multiple Myeloma.Immunological dysregulation in multiple myeloma microenvironment.Novel agents and new therapeutic approaches for treatment of multiple myeloma.Identify multiple myeloma stem cells: Utopia?Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.MET/HGF pathway in multiple myeloma: from diagnosis to targeted therapy?RNA interference for multiple myeloma therapy: targeting signal transduction pathways.Simvastatin Protects Osteoblasts from the Deleterious Effects of the Liquid Milieu of Multiple Myeloma.The potential diagnostic power of extracellular vesicle analysis for multiple myeloma.MicroRNA expression patterns and target prediction in multiple myeloma development and malignancy.Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1.Targeting plasma cells: are we any closer to a panacea for diseases of antibody-secreting cells?Role of the Immune Response in Disease Progression and Therapy in Multiple Myeloma.Systemic modeling myeloma-osteoclast interactions under normoxic/hypoxic condition using a novel computational approachMultiple myeloma cells alter the senescence phenotype of bone marrow mesenchymal stromal cells under participation of the DLK1-DIO3 genomic region.Microenvironment drug resistance in multiple myeloma: emerging new players.
P2860
Q26765477-DB9DDAFE-3C51-4C80-9248-DAE055147929Q26823660-D5F212FD-101F-4C1A-9FEA-829C6432D338Q27010162-B8BEDD00-8B42-463B-AC12-CE7C15A2AF01Q27692033-51A55BAF-82FA-4678-9AF3-38A3897BBF3EQ28540339-B4E9E6EF-FC09-4E98-9CCA-BA7C1069A45DQ33416297-07491BDF-6C39-4288-AC04-9FB8DF4DADB4Q33443411-961AF57F-A12D-44FC-872F-60C9842A07D1Q33714724-6EECC869-B389-46F7-8459-5D79D1162A51Q33875590-CDB7862F-3512-48E8-BEF1-4C9497DF2823Q33939162-7ADB871E-2496-4E11-84DC-4CF3B9E48701Q34103913-3326ECB7-17EA-48FA-8302-A9DF40C65E06Q34309899-FBC486A4-ED8D-4058-A7B5-D1903CB51272Q34556156-E786C5DC-E0F8-4CC1-A4AF-7422DB4A4023Q34876626-718EFEE8-91C7-4672-ACA3-5436BD30DCE6Q34898664-E52995F7-F518-43F2-A781-A3F8721E87ABQ35067806-622EC9E7-4219-40BF-B383-0B879AA81E5EQ35692401-12E456B8-09C9-4997-B3F4-BB94563CAE85Q35778467-5CF7D1CB-CB78-43DF-AE57-9B85A6C686F3Q36240614-E39AE2EA-D53C-488C-B089-D39BC14CA6D6Q36544516-7D48B206-647E-45D8-B866-A5B20FB682EDQ36750576-D9A7A70E-4F82-477B-9514-EAA87A4E1456Q37687419-BAF01A4F-CC5E-4863-85FA-1B54D56862B5Q38165960-3274AC1B-74DD-4B2F-9DF9-D5AB5044D935Q38176293-A06F6927-93AB-48E7-B524-E44CB79B5020Q38190971-E1CBABBF-20E4-46E9-85BB-2505C39EC7CEQ38228353-1D8D799D-936B-413E-B4F3-B7E7FBD5A14EQ38261677-A1901545-6223-4F03-8BF9-0C251CFAA701Q38332486-C222E077-37F6-4056-8AAB-40A4391C1435Q38462720-2D9B431A-B1C1-41D1-BDE0-39F3EA8CA44AQ38476204-87D91088-E0D4-4056-83E1-CFDB908EB315Q38550480-6D1BAB0C-179B-4784-BAE4-C150E4DEB90AQ38598988-FCAF849B-51FE-49C0-868B-A38EC3561194Q38670495-2BA58837-5725-499B-87DB-15586E95995FQ38689170-87EBF18A-9443-44CD-B036-530AEB689F6FQ38720340-9C23A148-E15A-4145-A300-A2801B6A4314Q38728585-953B29E7-0015-4994-8DFD-485C6665DF68Q38815399-7A714919-A6FA-4804-B2ED-92DB7EFD2B9CQ38843122-EC03DCAE-2C34-483E-B7FB-A780ABCC3C9AQ38885705-CDE218C4-2A4A-4D34-8EB1-E72E53291F5FQ38913083-B0301A40-324C-45C5-805F-2B26A9F5AEBC
P2860
Bone marrow microenvironment in multiple myeloma progression.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Bone marrow microenvironment in multiple myeloma progression.
@en
type
label
Bone marrow microenvironment in multiple myeloma progression.
@en
prefLabel
Bone marrow microenvironment in multiple myeloma progression.
@en
P2093
P2860
P921
P356
P1476
Bone marrow microenvironment in multiple myeloma progression
@en
P2093
P2860
P304
P356
10.1155/2012/157496
P577
2012-10-03T00:00:00Z